Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Engene Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. This distribution indicates that the company is pursuing multiple patent applications simultaneously, requiring coordination across different technical groups within the patent office.
The busiest examiner for the portfolio is BURKHART, MICHAEL D, who is responsible for 1 busiest examiner pending action. While this examiner is the most active, they only handle a portion of the total 3 pending office actions. The presence of 2 distinct art units suggests that the company's intellectual property spans different specialized sub-sectors within the broader biotechnology field.
With 3 distinct examiners involved, the prosecution strategy must account for varying examiner styles and art unit standards. The current workload is spread across these individuals, as the 1 busiest examiner pending action represents only a fraction of the total. This diversity in examiner assignment requires a specific approach to response preparation for each individual matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | BURKHART, MICHAEL D | — |
| 17438921 | REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE | ROGERS, JAMES WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | BURKHART, MICHAEL D | — |
| 18277944 | COMBINATION GENE THERAPY FOR TREATMENT OF METASTATIC CANCER | POLIAKOVA-GEORGAN, EKATERINA | — |
| 17438921 | REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE | ROGERS, JAMES WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18821962 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | BURKHART, MICHAEL D | — | §101DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18277944 | COMBINATION GENE THERAPY FOR TREATMENT OF METASTATIC CANCER | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 17438921 | REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Non-Final OA | — | Pending | Sep 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial